Fauna Bio (Company)

Fauna Bio (Company)

Developing a multi-omics human drug discovery platform inspired by disease resistance non-model organisms.

Fauna Bio is a Berkeley-based company developing a multi-omics human drug discovery platform inspired by disease resistance non-model organisms.

Fauna Bio's platform finds gene networks that turn on and off during disease protection time points in hibernators and verifies the translatability of potential targets using human genomics data and cross-species conservation.

The company says that hibernating mammals are an excellent system for identifying drug targets because they can transiently protect themselves from problems similar to critically important human diseases, allowing the company to identify key protective genes that are turned on or off at medically-relevant times. They are naturally protected from numerous physiological insults that would be lethal to a non-hibernator:

The company says that despite all of these insults, these animals emerge healthy in the spring, and that, paradoxically, hibernators live considerably longer than expected for mammals of their size. Fauna Bio says it has the largest hibernation biobank in the world and is mining its genetic signatures to identify drug targets.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Fauna Bio funding round, April 2019
4,099,999
April 2019
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.